Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.

SHSE:603168 Stock Report

Market Cap: CN¥2.6b

Zhejiang Shapuaisi PharmaceuticalLtd Past Earnings Performance

Past criteria checks 0/6

Zhejiang Shapuaisi PharmaceuticalLtd has been growing earnings at an average annual rate of 29.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6.8% per year.

Key information

29.5%

Earnings growth rate

31.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate6.8%
Return on equity-4.9%
Net Margin-16.8%
Next Earnings Update30 Apr 2025

Recent past performance updates

Recent updates

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) Investors Are Less Pessimistic Than Expected

Aug 23
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) Investors Are Less Pessimistic Than Expected

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Shares May Have Run Too Fast Too Soon

Apr 09
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Shares May Have Run Too Fast Too Soon

Revenue & Expenses Breakdown

How Zhejiang Shapuaisi PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:603168 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24506-8527258
30 Jun 24540-7327072
31 Mar 24621727266
31 Dec 236452526664
30 Sep 236347921971
30 Jun 236118220758
31 Mar 235624020449
31 Dec 225504521160
30 Sep 225714522461
30 Jun 225934423195
31 Mar 2262653231111
31 Dec 2163036245102
30 Sep 21580923892
30 Jun 21526-1324154
31 Mar 21432-4524135
31 Dec 20347-5522327
30 Sep 20352-5924422
30 Jun 20389-3226026
31 Mar 20437-1128427
31 Dec 19516830627
30 Sep 19515-16531026
30 Jun 19544-15233425
31 Mar 19568-14835026
31 Dec 18607-12636227
30 Sep 187337739234
30 Jun 1885010742842
31 Mar 1890513745034
31 Dec 1793914646829
30 Sep 1795321648115
30 Jun 179262624720
31 Mar 179452744660
31 Dec 169792764940
30 Sep 169422564620
30 Jun 169111954460
31 Mar 169411864720
31 Dec 159221764600
30 Sep 158871594510
30 Jun 158651524380
31 Mar 158171404110
31 Dec 147661313760
30 Sep 147461313570
30 Jun 147151233440
31 Mar 146621143130
31 Dec 136281043020

Quality Earnings: 603168 is currently unprofitable.

Growing Profit Margin: 603168 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603168 is unprofitable, but has reduced losses over the past 5 years at a rate of 29.5% per year.

Accelerating Growth: Unable to compare 603168's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 603168 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 603168 has a negative Return on Equity (-4.89%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 00:07
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jing QiangChina International Capital Corporation Limited